European regulators withdraw Amgen's Tavneos over questionable data

European regulators announced they are pulling Amgen's rare disease drug Tavneos from the European market after reviewing data they deemed incorrect and misleading.

The authorities said the data supporting the drug's efficacy and safety were not reliable, leading to skepticism and the decision to remove the product.

Amgen had previously marketed Tavneos for a rare disease, but the withdrawal reflects regulatory concerns and may affect the company's European operations.

The move underscores the importance of robust clinical data for drug approvals and could influence investor sentiment toward Amgen.